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Abstract 
Most cancer patients receive chemotherapy at some stage of their treatment which makes improving the 
efficacy of cytotoxic drugs an ongoing and important goal. Despite large numbers of potent anti-cancer agents 
being developed, a major obstacle to clinical translation remains the inability to deliver therapeutic doses to a 
tumor without causing intolerable side effects. To address this problem, there has been intense interest in 
nanoformulations and targeted delivery to improve cancer outcomes. The aim of this work was to demonstrate 
how vascular endothelial growth factor receptor 2 (VEGFR2)-targeted, ultrasound-triggered delivery with 
therapeutic microbubbles (thMBs) could improve the therapeutic range of cytotoxic drugs. 
Methods: Using a microfluidic microbubble production platform, we generated thMBs comprising 
VEGFR2-targeted microbubbles with attached liposomal payloads for localised ultrasound-triggered delivery of 
irinotecan and SN38 in mouse models of colorectal cancer. Intravenous injection into tumor-bearing mice was 
used to examine targeting efficiency and tumor pharmacodynamics. High-frequency ultrasound and 
bioluminescent imaging were used to visualise microbubbles in real-time. Tandem mass spectrometry 
(LC-MS/MS) was used to quantitate intratumoral drug delivery and tissue biodistribution. Finally, 89Zr PET 
radiotracing was used to compare biodistribution and tumor accumulation of ultrasound-triggered SN38 
thMBs with VEGFR2-targeted SN38 liposomes alone. 
Results: ThMBs specifically bound VEGFR2 in vitro and significantly improved tumor responses to low dose 
irinotecan and SN38 in human colorectal cancer xenografts. An ultrasound trigger was essential to achieve the 
selective effects of thMBs as without it, thMBs failed to extend intratumoral drug delivery or demonstrate 
enhanced tumor responses. Sensitive LC-MS/MS quantification of drugs and their metabolites demonstrated 
that thMBs extended drug exposure in tumors but limited exposure in healthy tissues, not exposed to 
ultrasound, by persistent encapsulation of drug prior to elimination. 89Zr PET radiotracing showed that the 
percentage injected dose in tumors achieved with thMBs was twice that of VEGFR2-targeted SN38 liposomes 
alone. 
 
Ivyspring  
International Publisher 
Theranostics 2020, Vol. 10, Issue 24 
 
 
http://www.thno.org 
10974 
Conclusions: thMBs provide a generic platform for the targeted, ultrasound-triggered delivery of cytotoxic 
drugs by enhancing tumor responses to low dose drug delivery via combined effects on circulation, tumor drug 
accumulation and exposure and altered metabolism in normal tissues. 
Key words: Microbubble; ultrasound; VEGFR2; nanoformulation; colorectal cancer 
Introduction 
A major obstacle to improving cancer outcomes 
is effective tumor-targeted drug delivery with 
minimum off-site toxicity. Despite large numbers of 
anti-cancer drugs being developed, their clinical use is 
often precluded by poor efficacy, intolerable side- 
effects and/or drug resistance. 
Advanced drug delivery systems developed to 
overcome these problems, such as liposomes and 
nanoparticles (NPs), have not yet demonstrated 
widespread clinical impact. A recent count showed 50 
different NPs currently in clinical trials but only 2 
were FDA/EMA approved from 2016-2019 [1]. This is 
due, in part, to a lack of clear pharmacological 
evidence of improved efficacy compared with 
conventional drug delivery and a lack of 
understanding of the mechanisms by which NP 
formulations elicit their response. For example, a 
recent meticulous study showed in multiple tumor 
types that active transport may be required [2]. Using 
‘Zombie’ mice, these researchers showed that active 
uptake of NPs via transendothelial pathways was 
predominant, potentially warranting a shift to active 
tumor targeting and away from the reliance on 
passive mechanisms involving enhanced permeability 
and retention (EPR) [2, 3]. However, multiple 
mechanisms including active targeting, EPR and 
transcytosis [4] could all potentially contribute to 
effective uptake. Nevertheless, the role of active 
targeting via antibodies or ligands, is a major area of 
research in “EPR and beyond” [5] aimed at increasing 
NP uptake into tumors [6-9]. In addition, little 
understanding of the absorption, distribution, 
metabolism, excretion and toxicity (ADMET) as well 
as inadequate tumor accumulation have proved 
challenging for nanodrug and nanoparticle 
therapeutics, thus precluding the use of more potent 
and highly toxic drugs in nanoformulations [10, 11]. 
To address some of these problems, several 
actively targeted and triggered systems are being 
developed where multiplexed particles and external 
energetic triggers (ultrasound [US], heat, light) or 
intrinsic tumor triggers (pH, redox) combine for 
tumor-specific drug delivery [12]. This combination 
approach to anti-cancer drug targeting may provide 
the required improvement in cancer outcomes with 
improved quality-of-life using existing or future 
agents. This is of particular significance when 
considering cancer incidence and demographics 
where for example in colorectal cancer (CRC), 
incidence is strongly related to age and rises steeply 
from 50-54 years with the highest rates seen in the 85 – 
89 age group [13], a group projected to almost double 
over the next 25 years [14]. This population may 
therefore be more suited to less invasive, low dose or 
adaptive therapies that control rather than cure 
cancer. 
Microbubbles (MBs) are micron-sized gas-filled 
phospholipid-shelled spheres, clinically approved for 
contrast-enhanced US imaging, which also show 
promise as vehicles for drug delivery [15-17]. The first 
use of MBs for improving tumor drug delivery was 
via co-injection with free drug with the application of 
low-intensity US to facilitate drug uptake by 
“sonoporation”, the formation of pores due to the 
biomechanical response to oscillating MBs [18-20]. 
Indeed this method has been examined in several 
clinical trials [21, 22] with some encouraging partial 
responses in both hepatic metastases and inoperable 
pancreatic cancer in early Phase I trials. However, 
more recent pre-clinical studies suggest that the most 
effective drug delivery by MBs is mediated by 
liposomes attached to the MB shell [23-25]. In this 
way, US-induced oscillation or collapse of the MB can 
affect local release and delivery of drug into the target 
tissue [26]. Furthermore, recently described 
mathematical and single bubble models [27] using 
fluorescently labelled, targeted MBs bound at a 
surface, identified physical mechanisms of drug 
release and transport following US exposure which 
may involve acoustic streaming, a phenomenon 
known to be generated by an oscillating bubble close 
to a border or wall [28]. 
Due to their micron size, MBs are intra-vascular 
agents; therefore actively targeting tumor endothelial 
markers (such as VEGFR2 or αvβ3 integrin) have been 
used to enhance the imaging of tumor vasculature 
[29-31] and also to target liposomes [10, 11, 32]. 
VEGFR2 lends itself to this role as it is upregulated in 
most solid tumors, including CRC [33, 34]. Smith et al. 
showed that VEGFR2 (and VEGFR3) was widespread 
in vessels of malignant tissues of the colon, breast and 
lung compared with matched normal controls [34]. 
VEGF/VEGFR2 blockade has also proved effective in 
treating advanced metastatic CRC [35]. Molecular 
imaging with VEGFR2 targeted MBs has been used 
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for monitoring therapy effects in an experimental 
CRC model [36] and clinically for breast, ovarian, 
prostate [37, 38] and renal cell cancer imaging [39] 
demonstrating widespread potential for VEGFR2 in 
cancer imaging and targeting. 
Irinotecan ([1,4’-Bipiperidine]-1’-carboxylic acid, 
CPT-11) is a chemotherapy drug used in primary and 
secondary line treatment of CRC (FDA approval 
given in 1998). Irinotecan is a prodrug, requiring 
activation by carboxylesterases to form SN38 (7-Ethyl- 
10-hydroxy-camptothecin), its active metabolite 
which is up to 1000 times more toxic. SN38 is 
detoxified by the polymorphic enzyme UGT1A1 to 
SN38 glucuronide (SN38G) [40]. Only a fraction of the 
administered irinotecan dose is converted to SN38, 
with the remaining drug being metabolized by 
CYP3A4 (and possibly CYP3A5) or excreted via 
hepatic or renal transport [40, 41]. SN38 causes cell 
death by inhibiting topoisomerase I (Topo I), an 
enzyme vital to DNA replication and transcription 
[40, 42]. This induces irreversible double-strand 
breaks and subsequently cell death in proliferating 
cells. Although SN38 shows in vitro efficacy as an 
anti-cancer agent, it is extremely hydrophobic and the 
fact that it cannot be dissolved in any 
pharmaceutically acceptable solvent has precluded its 
direct use. 
We have previously developed a flexible 
microfluidic MB production platform [43] that allows 
on-chip assembly of therapeutic MBs (thMBs) (see 
Figure 1A for schematic) of defined size and lifetime 
[44] and showed US-triggered model drug release 
from liposomally-loaded MBs in vitro [45, 46]. In this 
study we have engineered thMBs with either the 
prodrug irinotecan or its highly toxic metabolite SN38 
and investigated their biodistribution, efficacy and 
mechanisms of action in vivo. Using this approach, we 
have shown that thMBs can deliver effective doses of 
highly toxic drugs to tumors resulting in tumor 
growth inhibition without toxic side effects and may 
therefore provide the means to formulate existing 
potent but toxic drugs, novel drug combinations or 
previously “hard to deliver” drugs for cancer therapy. 
Methods 
Reagents and materials 
Lipids used for MB and liposome production 
 
 
Figure 1. VEGFR2 targeting of therapeutic microbubbles in human colorectal cancer. (A) Schematic depiction of a thMB (B) HCT116 CRC xenografts 
immunostained for CD31 and VEGFR2 with percentage of VEGFR2/CD31 double positive blood vessels related to tumor size presented (median with 95% confidence levels are 
denoted, **p = 0.004, Mann-Whitney U Test, two tailed). (C) The SMS (HF-US signal from VEGFR2-bound MBs minus the HF-US signal from isotype-control MBs) binned against 
tumor volume shows the specific binding of VEGFR2-targeted MBs in vivo (median with 95% confidence levels are denoted, not statistically significantly different). (D) Targeted 
microbubbles (MBs) or thMBs both with VEGFR2 targeting were flowed over SVR or PAE/KDR endothelial cells (both VEGFR2-expressing) and SW480 CRC cells (non-VEGFR2 
expressing). The percentage of cells with MBs bound was calculated (see ‘Quantification of VEGFR2-targeted MB binding’ in the Methods section). Mean and SEM are plotted. 
Two-way repeated measures ANOVA comparing between the MB type within the same cell type shows no significant differences in binding. (E) Bioluminescent imaging of mice 
injected with either isotype-targeted luciferin MBs or VEGFR2-targeted luciferin MBs. The average radiance measured from the pairs of mice are shown (n = 5 pairs). Fitted with 
a one-phase association curve, paired t-tests, one tailed at each time point p < 0.05 for all. The curve-fitted mean and SEM are shown (R2 isotype = 0.981, R2 VEGFR2 = 0.998). 
Theranostics 2020, Vol. 10, Issue 24 
 
 
http://www.thno.org 
10976 
were from Avanti Polar Lipids (Alabaster, AL, USA). 
Texas Red® 1,2-dihexadecanoyl-sn-glycero-3- 
phosphoethanolamine, triethylammonium salt (Texas 
Red® DHPE), tissue culture reagents and neutravidin 
were all from Invitrogen, Life Technologies (UK). 
Cardiolipin, sucrose, manganese sulfate, 
4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid 
(HEPES), ethylenediamine tetraacetic acid (EDTA), 
dimethyl sulfoxide (DMSO), irinotecan 
hydrochloride, ethyl-10-hydroxycamptothecin 
(SN38), tolbutamide and calcium ionophore A23187 
were all from Sigma-Aldrich (St Louis, MO, USA). 
7-ethyl-10-(4-amino-1-piperidino) carbonyl-
oxycamptothecin (SN38G) and irinotecan-d10 
hydrochloride were from Santa Cruz Biotechnology 
Inc. (Dallas, Texas, USA). Luciferin was purchased 
from Promega (Madison, WI, USA). 2,5- 
dioxopyrrolidin-1-yl3-oxo-1-(phenyldisulfanyl)-7,10,1
3,16,19,22,25,28,31,34,37,40,43,46,49,52-hexadecaoxa-4
-azapentapentacontan-55-oate (SPDP-dPEG1k-NHS 
ester) was purchased from Quanta Biodesign Ltd (US) 
and N-(3-Maleimido-1-oxopropyl)-L-α-phosphatidyl-
ethanolamine, Distearoyl (DSPE-Maleimide) was 
purchased from NOF Europe GmbH (Germany). 
89Zr-oxalate was purchased from Perkin Elmer 
(US)/BV cyclotron (Netherlands). All other chemicals 
were purchased from Sigma Aldrich (UK) and were 
used without any further purification. 
Jupiter® 10 µm Proteo(C12) 90 Å, LC Column 
250 × 10 mm and Jupiter® 10 µm C4 300 Å, LC 
Column 250 × 10 mm HPLC columns were purchased 
from Phenomenex LTD (UK) while a Superdex-200 
10/300 HPLC column was purchased from Sigma 
Aldrich (UK). PD-10 size exclusion desalting columns 
were purchase from GE Healthcare (UK) and Amicon 
ultra-centrifugal filters were purchased from Sigma 
Aldrich (UK). 
HPLC analysis was performed on a Shimadzu 
Prominence LC system running Laura 3 software 
from LabLogic and an ALC PK121R centrifuge was 
used as part of the 89Zr-liposome purification/ 
filtration process. 
Cell lines 
SW480, SW620 and HCT116 human CRC cell 
lines were obtained from ECACC (ecacc.org.uk). 
MC38 luc11A mouse syngeneic CRC cells, expressing 
luciferase were a kind gift from Professor R. D. 
Beauchamp, University of Vanderbilt, USA under a 
Materiasl Transfer Agreement. SVR murine 
endothelial cells were purchased from ATCC. Porcine 
aortic endothelial cells transfected with the human 
VEGFR2 gene (PAE/KDR) were a kind gift from 
Professor L Claesson-Welsh, University of Uppsala, 
Sweden. Cells were maintained in RPMI with 10% 
(v/v) fetal calf serum (FCS, Sigma-Aldrich, St Louis, 
MO, USA), apart from the PAE/KDR cells which 
were cultured in Ham’s F12 medium supplemented 
with 10% FCS. The SVR cells were cultured in 
high-glucose DMEM with 5% FCS. All cells were 
maintained at 37°C in 5% CO2. All human cell lines 
were authenticated in-house by tandem repeat (STR) 
profiling and screened negative for mycoplasma. 
Mouse models 
All experiments were performed following local 
ethical approval and in accordance with the UK 
Animals (Scientific Procedures) Act 1986. CD-1® nude 
mice were bred in-house under license from Charles 
River Laboratories (Wilmington, MA, USA) and 
maintained in specific-pathogen free conditions in 
individually ventilated cages (IVCs) with free access 
to water and food. 
Human CRC cells were used to establish 
xenografts on the flank of 5-7 week old female CD1 
nude mice, as described previously [47]. The numbers 
of mice (n) per group are detailed in each figure. 
High-frequency ultrasound imaging (HF-US) 
Tumors were imaged using a Vevo 770 high- 
frequency ultrasound system (Fujifilm VisualSonics 
Inc., Ontario, Canada) with 40 MHz (RMV-704) and 
25 MHz (RMV-710B) transducers, as previously 
described [48]. 
Contrast enhanced US and quantitative 
molecular imaging with US destruction- 
replenishment and Target-Ready Micromarker 
(Fujifilm VisualSonics Inc., Ontario, Canada) were 
performed as previously described [31] using 27g tail 
vein catheters (SAI Infusion Technologies, IL, USA) 
and an infusion syringe pump (Aladdin, World 
Precision Instruments, UK). 
Bioluminescence imaging (BLI) 
Light microscopy was used to measure the 
concentration and mean diameter of MBs and DLS 
was used to measure the mean diameter of liposomes. 
Using these parameters, we calculated that 100 µL 
liposome-loaded MBs (Target-Ready MicroMarker), 
corresponding to 1 × 108 microbubbles carried 
approximately 340 liposomes per MB. This was 
injected via the tail vein into MC38 luc11A tumor 
bearing mice. MBs were targeted using biotinylated 
anti-VEGFR2 antibody or isotype control antibody as 
described [31]. Pairs of mice with similar-sized tumors 
were injected via tail vein catheters to allow 
simultaneous imaging of targeted and untargeted 
liposomes. Auto exposure settings on an IVIS 
Spectrum (Perkin Elmer, Walton, MA, USA) were 
used for in vivo imaging (maximum one min exposure 
time) and BLI was performed every two min. Living 
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image software version 4.4 was used to analyze BLI 
signals. Auto ROIs with a threshold of 14% were used 
to calculate average radiance (photons/second/cm2/ 
steradian). 
Quantification of VEGFR2-targeted MB 
binding 
In vitro binding efficiency of microfluidically- 
generated VEGFR2-targeted MBs and thMBs (see 
On-chip generation of thMBs for details) was assessed 
as previously described [43], using flow rates of 0.3 - 
0.6 mL/min. The percentage of cells with MBs bound 
was calculated using the following equation: 
 
 
 
Generation and characterization of luciferin 
liposomes 
Luciferin encapsulation into liposomes was 
performed by active acetate gradient loading through 
the liposome membrane [49]. The shell was composed 
of 56:4:40:0.1 mol% of DSPC:DSPE-Biotin-PEG2000: 
Cholesterol:Texas Red® DHPE. 
Concentrations and size distributions of 
liposome preparations were determined using a 
Q-nano instrument (Izon Science Ltd, Oxford, UK). 
The encapsulated concentration of luciferin was 
determined using an LS55 Fluorescence Spectrometer 
(Perkin Elmer Inc., UK) against a calibration curve of 
free luciferin. 
Generation and characterization of irinotecan 
liposomes 
The lipid shell was composed of 63:32:5:0.1 mol% 
DSPC:Cholesterol:DSPE-Biotin-PEG2000:Texas Red® 
DHPE. Irinotecan encapsulation was performed by 
the manganese sulfate pH gradient method, as 
previously described [50]. Liposomes were sized and 
their concentration determined by Q-nano (Izon 
Science, Oxford, UK). The stability of liposomes was 
examined by measuring the irinotecan concentration, 
size distribution and liposome concentration for a 
sample that was stored at 4 °C over a period of 8 
weeks. Encapsulated irinotecan was quantified by 
HPLC (see below for HPLC methods). 
Generation and characterization of SN38 
liposomes 
The lipid shell of SN38 liposomes was comprised 
of 57:39:4:0.1 mol% of DSPC:Cholesterol:DSPE-Biotin- 
PEG2000:Texas Red® DHPE. 11% by weight of 
cardiolipin was also added to the shell. SN38 was 
dissolved in 0.1 M ammonium hydroxide to 2 mg/mL 
and the encapsulation procedure was carried out as 
previously described [51]. Liposomes were frozen in 
aliquots in liquid nitrogen, dehydrated by freeze 
drying then stored at 4 °C until required. Samples 
were rehydrated prior to use with 10 mM acetate 
buffer, pH 2 and filtered through a 200 nm filter. The 
encapsulated concentration of SN38 was measured by 
tandem mass spectrometry (see below for details). 
Liposomes were sized and their concentration was 
measured by DLS (Malvern) and NanoSight 
(Malvern). A Zetasizer (Malvern Instruments Ltd, 
UK) was used to measure the zeta potential, by 
passing a voltage through the sample and mixed 
measurement model phase analysis (M3-PALS) 
technology determined the mean reading in mV. The 
zeta potential was determined as -50.2 ± 7.7 mV, 
suggesting these liposomes would have long term 
stability with minimal aggregation. 
Synthesis of Df-PEG1k-SPDP 
The synthesis of Df-PEG1k-SPDP was carried 
out according to the method described [52]. First 
deferoxamine mesylate (39 mg, 60 µmol) was 
dissolved in DMSO (1 mL) and SPDP-PEG1k-NHS (65 
mg, 60 µmol, in DMSO (1 mL)) and diisopropyl-
ethylamine (7.8 mg, 60 µmol, 10.5 µL) were added. 
The reaction solution was stirred at room temperature 
for 4 h and monitored by HPLC (Jupiter® 10 µm 
Proteo (C12) 90 Å, Column, 250 x 10 mm). Upon 
completion the reaction mixture was poured into 
deionized water (0.5 mL) and the product was 
isolated by HPLC with an eluent system of solvent A 
= water (0.05 % TFA) and solvent B = acetonitrile (0.05 
% TFA) running at a gradient of 10 to 60 % solvent B 
over 30 min at a flow rate of 3 mL/min with a UV 
detector wavelength of 220 and 280 nm. 
Synthesis of Df-PEG1k-DSPE 
The synthesis of Df-PEG1k-DSPE was carried 
out according to the method described [52]. DSPE- 
maleimide (15 mg, 16 µmol) was suspended in 
distilled water (0.5 mL) and sonicated at 50 ºC until 
the solution became clear before being cooled to room 
temperature. Df-PEG1k-SPDP (46 mg, 30 µmol) from 
the previous step was then dissolved in distilled 
water (1 mL) and the pH was adjusted to 7.3 with 
NaOH (1 M). TCEP (0.1 M, pH 7, 1 mL) was added to 
the Df-PEG1k-SPDP solution and the mixture was 
incubated at room temperature for 10 min. Both 
solutions, Df-PEG1k-SPDP and DSPE-maleimide 
were combined and the pH was re-adjusted to 7.0 -7.3 
before the reaction mixture was incubated at room 
temperature for 4 h. After incubation the pH of the 
reaction mixture was adjusted to pH 2 – 3 and 
Df-PEG1k-DSPE was isolated by HPLC (Jupiter® 10 
µm C4 300 Å, column 250 × 10 mm) with an eluent 
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system of solvent A = water (0.05% TFA) and solvent 
B = acetonitrile (0.05% TFA) running at a gradient of 
50 to 90 % solvent B over 40 min at a flow rate of 3 
mL/min with a UV wavelength of 220 and 280 nm. 
Incorporation of Df-PEG1k-DSPE onto 
liposomes 
The lipid shell of SN38 liposomes was comprised 
of 57:39:4 mol% of DSPC:Cholesterol:DSPE-Biotin- 
PEG2000. 11% by weight of cardiolipin was also added 
to the shell along with 1 mol% of Df-PEG1k-DSPE. 
Zirconium-89 radiolabeling of Df modified 
liposomes 
First, freeze dried Df-modified liposomes were 
reconstituted in 10 mM sodium acetate buffer, pH 2 
(250 µL) before being passed through a 200 nm 
syringe filter. Next 89Zr-oxalate (230 µL, approx. 220 
MBq) was neutralized by the addition of Na2CO3 (2 
M, 105 µL) and the mixture was incubated at room 
temperature for 5 min. Following the incubation 
HEPES buffer (0.5 M, pH 7, 1 mL) and the filtered 
Df-modified liposomes (200 µL) were added. The 
radiolabelling solution was incubated at room 
temperature for 60 min followed by the addition of 
EDTA (0.1 M, 100 µL). Next the reaction mixture was 
applied to a PD-10 size exclusion purification column 
and 89Zr-liposomes were eluted in phosphate buffered 
saline (PBS). Finally the 89Zr-liposome mixture was 
filtered on a 100 kDa MWCO centrifuge filter at 12000 
rpm for 20 min to give 89Zr-liposomes in 
approximately 0.4 mL of PBS. For quality control 
analysis 50 µL of the purified 89Zr-liposomes were 
injected onto a Superdex 200 size exclusion column 
eluted with PBS at 0.8 mL/min. Df modified 
liposomes were successfully radiolabelled with 89Zr to 
give 41.2 ± 10.8 MBq (n = 3) of 89Zr-liposomes in a 
non-decay corrected radiochemical yield of 18.7% ± 
4.9 (n = 3). The radiochemical purity of 89Zr-liposomes 
was 87.1% ± 0.8 (n = 3) as determined by size 
exclusion HPLC. 
On-chip generation of therapeutic MBs 
The generation of thMBs was carried out in a 
microfluidic device as previously described [43, 44]. 
Briefly, 8 µL 2.5 mg/mL neutravidin was added per 
100 µL of liposomes and incubated for 20 min. This 
was then incubated with 2 mg/mL DPPC, DSPE- 
biotin PEG200 (95:5 mol%) lipid and 10 µL/mL C6F14 
liquid was added (Sigma-Aldrich, St Louis, MO, USA) 
to improve MB stability [44] before generating 
liposome-loaded microbubbles using a patented 
microfluidic chip-based system. The microbubbles 
were counted and sized by taking light microscopy 
images of the resulting microbubbles and 0.1 µg of 
biotinylated anti-mouse VEGFR2 antibody was added 
per 107 microbubbles and incubated for 20 min before 
injection. 
In vivo delivery and ultrasound triggering 
CD1 nude female mice aged 5-7 weeks were 
inoculated with 107 SW480 CRC cells on the right hind 
flank. After 7 days, mice were randomly assigned to a 
treatment group. ThMBs or free drug were 
administered via tail vein injection. Animals in the 
thMBs + trigger (T) group received an US pulse at the 
tumor site 4 min post MB injection using a custom- 
built single element ultrasound system (UARP) [45]. 
A 2.2 MHz, 10 µs ‘tone burst’ US pulse was generated 
by an unfocused transducer (V323, Olympus NDT, 
UK), with a peak negative pressure of 260 kPa that 
had a 1 kHz pulse repetition frequency (PRF). The 
total sonication time was 5 s. The US-trigger had an 
MI of 0.21 by Church approximation [53] and a 
thermal index in soft tissue of 0.09, both of which are 
considered safe for all diagnostic US applications. 
High-performance liquid chromatography 
(HPLC) 
For quantification of irinotecan loading into 
liposomes and final MB preparations, HPLC was 
used. Irinotecan was dissolved in DMSO to 2 mg/mL 
and a 6-point standard curve diluted 1:1 from 1 
mg/mL was prepared in methanol. thMB samples 
were diluted 1:1 in methanol, vortex mixed and 
centrifuged at 10,000 g for 4 min at 4°C to remove 
lipids. Irinotecan liposomes alone were diluted 1:10 in 
methanol then treated as the thMB sample. Samples 
were analyzed using a Waters Alliance 2695 HPLC 
(Waters Corporation, Milford, MA, USA) linked to a 
Waters 2996 Photodiode Array Detector detector. 10 
µL of sample was eluted using a stepwise gradient at 
a flow rate of 1 mL/min on a Hichrom RPB column 
(3.5 µm, 25 cm × 2.1 mm) (Hichrom Limited, UK). 
Mobile phase A consisted of 90% (v/v) dH20, 10% 
(v/v) methanol and 0.1% (v/v) formic acid, and 
mobile phase B consisted of 90% (v/v) methanol, 10% 
(v/v) dH20 and 0.1% (v/v) formic acid. The initial 
gradient of 90% A: 10% B was gradually increased to 
90% B over 7 min, held for 2 min and returned to the 
initial gradient over 1 minute and held at this to give a 
total run time of 15 min. The area under the curve at 
373 nm was calculated using Empower Pro software 
(Waters) and comparison to the standard curve was 
used to determine concentration of irinotecan in 
liposomes and in each MB preparation. These mobile 
phases allowed direct conversion to mass 
spectrometry. 
Tandem mass spectrometry (LC-MS/MS) 
Irinotecan, SN38 and SN38G were dissolved in 
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DMSO as fresh 1 mg/mL stock solutions and a 
6-point standard curve diluted 1:1 from 1 µg/mL was 
prepared in methanol. Mouse tumors and tissues 
were weighed and homogenized in methanol on ice 
using an Ultra Turrex® blender (Janke and Kunkel, 
IKA). A clear supernatant was obtained by 
centrifugation at 10,000 g for 4 min at 4 °C and 
analyzed by LC-MS/MS. An internal standard 
(irinotecan-d10 hydrochloride) was also prepared in 
methanol and spiked into each sample at a 
concentration of 1 µg/mL. Multiple reaction 
monitoring (MRM) mass spectrometry was 
performed on a Waters Quattro Ultima triple 
quadruple mass spectrometer with an electrospray 
ionization source operating in positive ionization 
mode (LC-MS/MS). Compounds were eluted using a 
stepwise gradient at a flow rate of 0.3 mL/min where 
mobile phase A and B were as described for HPLC 
above, on an Acuity UPLC BEH C18 column (1.7 µm, 
2.1 × 100 mm) (Waters Corporation, Milford, MA, 
USA). The column was heated to 40 °C. The initial 
gradient of 80% A: 20% B was gradually increased 
over 15 min to 80% B, then increased over 1 min to 
100% B and held for 4 min then returned to the initial 
gradient over 1 min and held for 14 min, with a total 
run time of 35 min. Instrument settings: Capillary 
voltage, 3.50 kV; Cone energy, 12 V; Source 
temperature, 120 °C; Desolvation temperature, 250 °C; 
Gas flow desolvation, 650 L/h; Cone, 60 L/h. MRM 
settings were optimized using pure irinotecan and 
SN38 as described previously [54], The peak area 
calculated using Masslynx software (Waters 
Corporation) and comparison to the standard curve 
was used to determine drug concentrations. 
For quantification of SN38 loading into 
liposomes and final MB preparations, LC-MS/MS 
was used. Samples were prepared as previously 
stated for irinotecan liposomes and MBs and analyzed 
using the LC-MS/MS conditions stated below for 
SN38 tissue samples. 
Tissues were weighed and homogenized in 
methanol spiked with 10 ng/mL internal standard 
tolbutamide (Sigma-Aldrich) using a Bead Ruptor 24 
Bead Mill Homogenizer (OMNI International Inc.) 
with 2.8 mm zirconium ceramic oxide beads. A clear 
supernatant was obtained by centrifugation at 10,000 
g for 4 min at 4 °C. Standard curves for SN38 and 
SN38G were prepared as described previously with 
tolbutamide spiked methanol, and analyzed by 
LC-MS/MS using mobile phases and column as 
described above. The initial gradient of 80% A: 20% B 
was gradually increased over 16 min to 100% B then 
returned to the initial gradient over the following 4 
min and held, for a total run time of 25 min. 
Instrument and MRM settings were as described 
above. 
Positron Emission Tomographic Imaging of 
radiolabelled liposomes and therapeutic MBs 
SW480 tumor bearing CD1 nude female mice 
were injected intravenously with 100 µL of either 
89Zr-labelled SN38 liposomes (n = 15 mice) or thMBs 
carrying the 89Zr- labelled SN38 liposomes (n = 15 
mice). Both were conjugated to anti-VEGFR2 
antibodies. The injections contained the same number 
of radiolabeled liposomes per MB (~340) and at 2 MBq 
per injection. The therapeutic MB group was also 
subject to an US-trigger as described in ‘In vivo 
delivery and ultrasound triggering’. Imaging was 
performed using the Inveon Multimodality TM PET 
scanner (Siemens Medical Solutions) for 20 min in a 
supine position after 1, 24 and 72 h post-injection. Five 
mice per time point were imaged and had their tissue 
collected after imaging. Data were acquired using 
Inveon Acquisition Workplace (IAW) software 
(Siemens) version 2.1 and analyzed using Inveon 
Reconstruction Workplace (IRW) software (Siemens) 
version 2.2.0. Images were reconstructed using the 
order subset expectation maximization (OSEM)/ 
maximum a posteriori (MAP) algorithm. 
Tissues were weighed and were counted in a 
gamma counter (Perkin Elmer, 1480, Wizard 3) for 20 
s per sample. The gamma counter provides a “counts 
per minute” parameter. These data were imported 
into an Excel spreadsheet where the counts per 
minute were converted into activity by conversion 
into disintegrations per minute; by multiplying the 
efficiency of the gamma counter for 89Zr. Activity was 
decay corrected to the time of injection and converted 
into a concentration using the ex vivo tissue weight (in 
kilobecquerel per gram). All mice in which 89Zr 
radioactivity in the tail exceeded 10% of the injected 
dose were excluded from analysis. 
Tissue processing, immunohistochemistry and 
pharmacodynamic analysis 
Paraformaldehyde-fixed tumors and tissues 
were processed using a tissue processor and 
embedded in paraffin. 4 µm central sections were cut 
and one section from each sample was stained with 
hematoxylin and eosin (H and E). Slides were scanned 
using an Aperio digital slide scanner (AT2, Leica 
Biosystems) at ×20 magnification with ImageScope 
software (Leica Biosystems,) at 0.5 µm/pixel. JPEG 
compression quality 70 was used to quantify digital 
slide images for mitotic bodies, which were counted 
by a reviewer blinded to the experimental groups. 
ImageScope was then used to manually annotate the 
boundary of the tumor area on the digital slide, in 
order to calculate the number of mitoses/mm2. 
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IHC detection of CD31-positive blood vessels 
was performed as previously described [55] except 
heat-mediated antigen retrieval in citrate buffer, pH 
6.0 was used. Slides were digitally scanned at ×20 
magnification to facilitate image analysis and scoring. 
For quantification of CD31 positive blood vessels, ten 
0.25 mm2 boxes were placed randomly across the 
tumor section using RandomSpot software version 
6.02 [56] and the number of CD31-positive vessels 
counted as described [57]. 
VEGFR2-positive blood vessels were identified 
and quantified in tissues using immunostaining with 
an anti-mouse VEGFR2 antibody (55B11, Cell 
Signaling Technologies). Sections were de- 
paraffinised before heat-mediated antigen retrieval in 
Tris/EDTA/Tween-20 (10 mM/1 mM/0.05%) buffer 
pH 9.0. Endogenous peroxidases and casein were also 
blocked, and then sections were incubated with rabbit 
anti-mouse antibody at 1:100 dilution for one hour at 
room temperature. After washing, a rabbit 
Envision-HRP polymer and DAB were used for 
visualization (Dako, United Kingdom). Slides were 
digitally scanned at ×20 magnification. VEGFR2 
positive vessels in each tissue section were counted by 
a blinded observer. 
Cleaved Caspase 3 staining of the tumors as a 
biomarker of apoptosis [47] and phosphorylated 
histone H2AX (pH2AX) staining were carried out 
manually as described, except the latter antibody was 
applied at a 1:400 dilution [58]. pH2AX was used as a 
surrogate marker for irinotecan efficacy, as 
topoisomerase 1 inhibition causes single-strand DNA 
breaks, which are then converted to double-strand 
breaks during S phase. The entire tumor area was 
digitally scanned at ×20 magnification. Annotated 
tumor boundaries were used as regions of interest for 
automated analysis. An in-house developed 
algorithm was used to extract each region and block 
process the tissue at full resolution, using color 
deconvolution to separate staining channels into 
hematoxylin and DAB images, for analysis 
independently [59]. The intensity of DAB staining was 
co-localized with a basic binary mask of foreground 
tissue (generated by thresholding of hue, saturation 
and intensity channels), in order to obtain the total 
percentage of positive pixels within the tumor area. 
The resulting percentage positive pixels were divided 
by the tumor area, as described previously. 
Transmission electron microscopy (TEM) 
Liposomes and thMB morphology was 
evaluated using negative staining technique with 
transmission electron microscope (TEM) JEM1400, 
120KV instrument (JEOL, USA). For sample 
preparation, 8 µL of diluted liposome sample 
(1011/mL) or thMB sample (109/mL) was placed on a 
coated carbon grid. The solution was left on the grid 
for 30 s, and the excess liquid dried out with filter 
paper. Another 8 µL of 1% uranyl acetate was 
subsequently added to stain the sample, incubated for 
15 s, then the excess liquid was removed with filter 
paper, and was finally dried at room temperature. 
Quantitating perivascular inflammation 
For perivascular inflammation scoring in the 
livers of treated animals, H and E stained liver 
sections were digitally scanned at ×20 magnification. 
The area of inflammation (µm2) per tissue section was 
determined by a blinded observer using ImageScope. 
Percentage inflammation was determined by dividing 
area of inflammation (µm2) by area of liver section 
(µm2) × 100. 
Alanine aminotransferase (ALT) liver enzyme 
analysis 
Plasma samples were analyzed at The Mary 
Lyon Centre, Pathology, Medical Research Council, 
Harwell, Oxfordshire, UK. A Beckman Coulter AU680 
clinical chemistry analyzer (Beckman Coulter, Inc., 
CA, USA) was used to determine ALT concentrations. 
Statistical analyses 
All statistical analyses were performed using 
GraphPad Prism version 8 software. Statistical tests 
used for each experiment are described in figure 
legends. 
Results 
VEGFR2 targeting of therapeutic 
microbubbles in human colorectal cancer 
We first assessed VEGFR2 as a candidate 
biomarker for tumor blood vessel-specific binding of 
thMBs in human CRC xenografts. This showed 
approximately 2.5× more VEGFR2 positive blood 
vessels in smaller tumors (up to 200 mm3) than larger 
tumors (up to 750 mm3) ex vivo (Figure 1B and Figure 
S1A-B). To relate the immunohistochemical detection 
of VEGFR2 positive blood vessels with functional 
VEGFR2 targeting in vivo, we used contrast enhanced 
US with quantitative analysis of VEGFR2 MB binding. 
Subtracted molecular signals (SMS) equating to the 
signal from VEGFR2-targeted MBs were higher (but 
not significantly different) in smaller than larger 
tumors (11 ± 2.4 versus 6 ± 2.5, respectively, Figure 1C 
and Figure S1 C-D) suggesting that in this model, 
there was sufficient VEGFR2 across all tumor sizes for 
it to be actively targeted by thMBs. 
To assess the potential for off-target binding, we 
examined VEGFR2 immunoreactivity in mouse 
tissues and determined SMS in vivo. VEGFR2 was 
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detected in the fenestrated endothelial cells of the 
liver sinusoids but not in the endothelial cells of the 
hepatic venules, with weaker staining in kidney 
cortex and red pulp of the spleen. These areas also 
demonstrated SMS signals in vivo from targeted MB 
binding (Figure S1E-F). Although VEGFR2 is not 
entirely tumor specific, drug release from thMBs 
bound to VEGFR2 in non-tumor vessels would 
potentially be avoided as the US-trigger is localized to 
the tumor site alone. 
thMBs were generated by attaching liposomes to 
the MB shell (see Figure S1G and [43]) and VEGFR2 
antibody was bound as described in the methods. 
Under flow conditions in vitro, thMBs showed specific 
binding to VEGFR2 positive cells (Figure 1D). Both 
mouse (SVR) and human (PAE/KDR) VEGFR2 
positive endothelial cells bound targeted MBs and 
thMBs at significantly higher levels (p < 0.0001, two- 
way repeated measure ANOVA) than SW480 CRC 
cancer cells which showed minimal binding of MBs. 
Furthermore, there were no significant differences in 
binding by VEGFR2-targeted MBs alone or thMBs on 
endothelial cells, confirming that addition of the 
liposomal payload did not affect targeting efficiency 
in vitro. 
We next assessed the ability of thMBs to target a 
payload in vivo, using luciferin as a model liposomal 
drug for delivery to luciferase-expressing mouse 
colorectal MC38 xenografts and quantified tumor 
bioluminescence (BLI) over time [49]. Tumor BLI in 
mice receiving intravenous VEGFR2-targeted 
luciferin MBs was significantly higher than in those 
targeted with an isotype-control antibody (Figure 1E 
and Figure S1G). Linear regression analysis of the 
curves showed no difference between the slopes but 
significant differences in the intercepts (p = 0.007) 
indicating that the rate of release of luciferin from 
MBs was constant but that there was greater initial 
delivery of luciferin to the tumor with VEGFR2 
targeting and ensuing uptake throughout the tumor 
due to its highly water soluble nature and the inherent 
leakiness of the luciferin liposomes. We therefore 
used VEGFR2-targeting in subsequent experiments to 
target drug loaded thMBs to the tumor vasculature 
and investigate US-mediated thMB delivery of 
cytotoxic drugs in vivo. 
Therapeutic microbubbles enhance tumor 
responses to irinotecan 
To determine if thMBs could enhance tumor- 
specific delivery of a chemotoxic payload in vivo, we 
produced thMBs containing irinotecan (Figure S2 and 
Tables S1A and S1B). Irinotecan is a member of the 
camptothecin class of drugs with proven survival 
benefits as a standard first-line therapy containing 
fluorouracil-leucovorin-irinotecan (FOLFIRI) with or 
without bevacizumab in CRC. However, severe 
adverse effects (diarrhea and neutropenia) often lead 
to altered dosing schedules or preclude its use [60]. 
We compared tumor drug concentrations, drug 
metabolism and tumor responses in vivo with and 
without an US-trigger using a bolus of 108 thMBs 
(intravenous injection volume of the thMBs ranged 
from 150-200 µL in order to maintain this) consistent 
with contrast-enhanced US imaging protocols in mice 
[61, 62]. This equated to approximately 2 mg/kg 
irinotecan per treatment (Tx), 25× lower than the 
standard therapeutic dose for mice [63]. 
The treatment groups and protocols used are 
shown in Figure 2A and B, respectively. The 
customised US-trigger [46] (+T) directed at tumors 
was a high amplitude, low frequency tone burst with 
a duration of only 5 s designed to induce MB bursting 
or cavitation within the tumor [45]. This had a 
Mechanical Index (MI) of 0.21 using the Church 
approximation [53] and a thermal index in soft tissue 
of 0.09, both of which are considered safe for all 
diagnostic US applications. In pilot studies, we 
showed that this US destruction pulse had no 
significant effect on the growth of human CRC 
xenografts (HF-US ratio to day 0 for vehicle was 5.47 ± 
1.06 and vehicle +T was 5.76 ± 0.98 (mean, ± SEM; n = 
4 and 6 per group respectively). 
As shown in Figure 2C, irinotecan thMBs +T 
significantly inhibited the tumor growth rate 
compared with the vehicle control across all imaging 
time points and with the equivalent dose of free 
irinotecan on day 18. Tumor mass was also 
significantly reduced compared to vehicle and tumor 
doubling time significantly increased (Figure 2D-E). 
The % tumor growth inhibition (%TGI) compared to 
vehicle (% TGI = 1- (treated final - treated day 0)/ 
(control final - control day 0) [64]) was 38% for free 
irinotecan and 50% for thMBs + T. In addition, if the 
free irinotecan is used as the control in the equation, 
the thMBs +T show a 19% TGI compared to free 
irinotecan. There was no significant reduction in 
tumor growth in the thMBs -T group (% TGI -4%) 
demonstrating that an US-trigger was essential for 
effective drug release, penetration and/or retention in 
tumors. Irinotecan-induced biomarker levels changed 
in all three treatment groups (Figure S3A-D) but were 
significantly enhanced with thMBs +T (tumors 
showed fewer mitotic cells, increased double strand 
breaks and apoptotic cells but no change in blood 
vessel density). Therefore, US-driven thMB delivery 
apparently increased the potency of irinotecan at 
these low doses. 
To determine if the enhanced tumor responses 
with thMBs +T were due to altered pharmacokinetics 
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(PK) of drug delivered in this way, we used 
LC-MS/MS to quantify levels of irinotecan and its 
active and inactive metabolites (SN38 and SN38 
glucuronide [SN38G] respectively) in tumors from all 
treatment groups, collected 72 h after the final 
treatment. Irinotecan and SN38 were detected only in 
tumors from the thMBs +T group (Figure 2F) with 
median (± range) levels of 47 (± 102) ng/g and 2.2 (± 
60.4) ng/g tissue, respectively. Both values lie within 
the effective therapeutic doses in vitro (data not 
shown). No SN38G was detected. Irinotecan and 
SN38 were below the limit of detection (LOD) in all 
tumors from the free drug and thMBs –T groups 
(Figure 2F) showing that the US-trigger was required 
for the enhanced tumor drug accumulation/retention. 
The extraction efficiencies, stability of compounds 
and LOD are shown in Tables S2A-C and Figure S4. 
Irinotecan and SN38 were also detected in other 
tissues of the thMBs +T group (Figure 2G). Irinotecan 
was present in kidney and spleen, with traces of SN38 
in a single kidney and single spleen. In the thMBs -T 
group, irinotecan and SN38 were only detected in 
colon where 4/7 (57%) had detectable irinotecan and 
4/8 mice (50%) had detectable SN38 levels. 1/7 (14%) 
or 2/7 mice (29%) also had detectable levels of 
irinotecan or SN38 respectively, in colon in the free 
drug group (Figure S5). This shows that both the free 
drug and thMBs -T groups had been exposed to 
irinotecan but that the drug had been metabolised and 
eliminated and was below the LOD in tumor and 
liver, indicating an altered PK response with thMBs 
+T delivery. 
We next compared the relative amounts of 
irinotecan and SN38 in tissues to assess irinotecan 
metabolism as a surrogate marker of drug release 
(LC-MS/MS cannot differentiate between liposomally 
encapsulated or unencapsulated ‘free’ drugs). Highest 
relative amounts of SN38 were found in tumor and 
colon suggesting greater conversion of irinotecan to 
SN38 in these tissues (Figure 2H). In contrast, there 
were relatively low amounts of SN38 in the liver 
suggesting limited conversion prior to elimination via 
hepatobiliary clearance. Persistent liposomal 
encapsulation of irinotecan and sequestration in cells 
of the mononuclear phagocytic system (MPS) through 
which NPs and liposomes are cleared [65-67], may 
explain this. In rodents, up to 50% of irinotecan is 
converted to SN38, whereas humans convert less than 
8% [68, 69]. This suggests that thMB +T targeted 
delivery of SN38 itself might be more clinically 
effective. 
There was no significant correlation between 
absolute amounts of irinotecan and SN38 in tumors 
(Spearman’s correlation r = 0.48, p = 0.3) or livers 
(Spearman’s correlation r = 0.59, p = 0.13), suggesting 
non-linear conversion kinetics in both tissues. This 
may reflect saturable carboxylesterase-converting 
enzymes or inaccessibility of drug for metabolism due 
to persistent encapsulation in intact liposomes. By 
contrast, ratios of irinotecan:SN38 in colon from all 
groups were close to 1 suggesting a linear conversion 
rate as indicated by a significant Spearman’s 
correlation (r = 0.835, p = 0.0007) between individual 
levels of irinotecan and SN38. This suggests direct 
conversion of irinotecan to SN38 or 
deglucuronidation of SN38G to SN38 in the gut 
microenvironment consistent with bacterial 
metabolism of irinotecan [70]. 
Free irinotecan shows rapid metabolism and 
excretion in vivo 
We next performed a small study to examine 
how tumor PK and biodistribution of irinotecan 
delivered via targeted US-triggered delivery 
compared with free drug at high dose (50 mg/kg, 
relevant to routine clinical doses) or at low dose (2 
mg/kg, relevant to the dose delivered by thMBs) 
(Figure 3). At 1 and 24 h post-injection of free drug, 
the levels of irinotecan, SN38 and SN38G were 
measureable indicating drug delivery and metabolism 
through to the glucuronidated form was possible in 
all tissues. The 50 mg/kg dose gave high circulating 
levels in serum at 1 hour with higher levels in liver, 
kidney and spleen and the lowest level in tumor. Low 
dose drug followed a similar pattern with tumor 
irinotecan levels at 1 hour equivalent to those 
measured at 72 h post thMB +T administration of the 
same drug dose. At 72 h post injection of free drug 
there was no detectable drug in any tissues except for 
irinotecan in a single kidney and spleen, showing that 
the altered PK observed with thMBs was not due to 
the use of a lower dose alone. 
SN38 delivery with US-triggered therapeutic 
microbubbles significantly inhibits tumor 
growth 
To determine if the benefits of thMB delivery in 
terms of improved PK and tumor responses could be 
extended to a more cytotoxic molecule, we 
investigated delivery of SN38 directly as its efficacy at 
very low doses would be appropriate to the thMB 
delivery platform. Free SN38 is poorly water soluble 
with a high partition coefficient (logP 2.65) and cannot 
be delivered in free drug form without an 
accompanying high concentration of solvent such as 
DMSO, thus encapsulation has been the subject of 
intense research [71-73] and at least one formulation 
has reached clinical trials [74]. SN38 was encapsulated 
in liposomes and used to formulate SN38 thMBs 
(Figure S6 and Tables S3A-B). The experimental 
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groups and dosing schedule used for in vivo 
evaluation of SN38 thMBs +T are shown in Figure 4A 
and B respectively and were used to deliver 0.4 
mg/kg SN38 per Tx. 
 
 
Figure 2. Therapeutic microbubbles enhance tumor responses to irinotecan. (A) Treatment groups used (n = number of mice per group). The abbreviated 
nomenclature used in subsequent figures is shown. (B) Schematic of the experimental protocol is shown with timing of each treatment (Tx) and 3D high frequency ultrasound 
(HF-US) imaging. The mean (± SEM) starting tumor volumes for each group were 65 (± 7.9) mm3 for vehicle, 76 (± 12.5) mm3 for free, 72 (± 11.5) mm3 for the thMBs -T (no 
US-trigger) and 85 ± (14.3) mm3 for the thMBs + T group which are not statistically significantly different at this time point. (C) Effect of thMBs on tumor volume (mean ± SEM) 
ratio to day 0. Unpaired Mann-Whitney test *1 p = 0.0152 (vehicle vs thMBs +T), *2 p = 0.0311 (vehicle vs free), **3 p = 0.0025 (vehicle vs thMBs +T), *4 p = 0.0229 (vehicle vs 
free), *5 p = 0.0152 (free vs thMBs +T), ****6 p < 0.0001 (vehicle vs thMBs +T). (D) Final tumor mass, unpaired Mann-Whitney test p = 0.036 (E) Tumor doubling time, unpaired 
Mann-Whitney test, *1 p = 0.036, *2 p = 0.0401. (F) Irinotecan and SN38 were only detected by LC-MS/MS analysis in tumors from the thMBs +T group at 72 h post final 
treatment. LOD indicates the drug was below the limit of detection. (G) Irinotecan and SN38 in tissues from the thMB +T group at 72 h post final treatment (median values are 
indicated). (H) Relative amounts of irinotecan and SN38 showing tumor and colon with highest relative levels of conversion of irinotecan to SN38. 
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Figure 3. Free irinotecan shows rapid metabolism and elimination in vivo. LC-MS/MS was used to measure the concentration of irinotecan and its metabolites, SN38 
and SN38G, in tumors and tissues. High dose (50 mg/kg) and low dose (2 mg/kg) equivalent to that used in thMBs (Figure 2) was delivered intravenously. Free drug was rarely 
detected after 24 h with only one kidney and one spleen of the three mice in this group showing detectable levels at 72 h using a high-dose of irinotecan. Data from a single 
injection of irinotecan per time point per mouse are shown except for 72 h where n = 3. 
 
There was significant inhibition of tumor growth 
at days 7 and 14 post treatment (Figure 4C). Reduced 
tumor masses and complete regression of one tumor 
in the thMB +T group were observed (Figure 4D). 
Tumor doubling times were increased or abolished 
(tumors regressed in volume) in the thMB +T group. 
Apoptosis and double-strand DNA breaks were also 
significantly increased as revealed by caspase 3 
(Figure 4F) and pH2AX staining (Figure 4G). The 
extremely low doses of drug (0.4 mg/kg) delivered by 
thMBs +T gave 93% TGI. This compared favorably 
with liposomal SN38 at 8 mg/kg previously shown to 
give 81-91% tumor growth inhibition in mouse CRC 
models [75-77]. 
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Figure 4. SN38 delivery with US-triggered therapeutic microbubbles significantly inhibits tumor growth. (A) Abbreviated nomenclature and treatment groups 
subsequently denoted in brackets used are shown (n = number of mice per group). (B) A schematic of the experimental plan is shown with each treatment (Tx, 0.4 mg/kg SN38) 
and 3D high frequency ultrasound (HF-US) imaging denoted. The mean (± SEM) starting tumor volumes for each group were 100 (± 13.2) mm3 for vehicle +T and 106 (± 16.6) 
mm3 for the thMBs +T group which were not statistically significantly different at this time point. (C) The mean (± SEM) ratio to day 0 tumor volume measured by 3D HF-US 
is shown. Unpaired Mann-Whitney test *1 p = 0.048, *2 p = 0.0159. (D - E) Final day tumor mass was measured and tumor doubling time calculated (negative tumor doubling 
times indicate tumor regression). The median value for each group is denoted by a line (neither statistically significantly different). (F - G) Apoptosis and double-strand breaks, 
the median (+ range) value for each group are denoted. Apoptosis p = 0.0159 and double-strand breaks p = 0.0317, unpaired Mann-Whitney test. (H) Biodistribution of SN38 
within all tissues 72 h post final treatment. No SN38G was detected. 
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SN38 was detected in all tumors where sufficient 
tissue remained at endpoint (4/5) for LC-MS/MS 
analysis. SN38 was also present at increased levels in 
other tissues but not in plasma (Figure 4H). However, 
SN38G was not detected suggesting that SN38 
remained encapsulated and/or released over time 
and was below the LOD. This is consistent with 
irinotecan thMBs +T. ThMB +T delivery increased 
tumor drug uptake/retention and/or exposure 
resulting in significant inhibition of tumor growth at a 
dose 20× less than that given in liposomally 
encapsulated SN38 studies [75-77]. 
Irinotecan treatment is often restricted by its 
dose-limiting side effects. Life-threatening diarrhea, 
neutropenia and myelosuppression are induced by 
the active SN38 [60]. None of the mice from the SN38 
thMB +T group (or previous irinotecan thMB groups) 
exhibited signs of such toxicity (Figure S7A-E) 
suggesting that retention of encapsulated drug in 
tissues following SN38 thMB +T delivery produced 
no detectable effects. 
89Zr-labelled SN38 thMBs +T show increased 
tumor drug accumulation and altered tissue 
pharmacokinetics compared to VEGFR2- 
targeted 89Zr-labelled SN38 liposomes alone 
One strategy to improve liposomal delivery to 
solid tumors to overcome poor penetration, poor drug 
potency and inefficient drug release has been to 
functionalize the surface of the liposome with 
targeting ligands including peptides, antibodies or 
aptamers and several actively targeted formulations 
are in clinical trials [78]. 
To directly compare targeted delivery by thMBs 
with a clinically relevant nanoformulation, we carried 
out 89Zr-radiolabelled distribution studies with 
longitudinal PET imaging in mice. Mice bearing 
human CRC xenografts were used to examine 
biodistribution and quantitate uptake of VEGFR2- 
targeted 89Zr-SN38 liposomes alone compared with 
89Zr-SN38 thMBs +T (depicted in Figure 5A). 
Radiolabelling of pre-formed liposomes incorporating 
a deferoxamine chelator was necessary as SN38 itself 
was not amenable to direct labelling with 89Zr due to 
its relatively small size. Treatment groups and 
protocols used are shown in Figure 5B and C 
respectively. 
PET images at 1, 24 and 72 h post intravenous 
injection with 89Zr-SN38 thMBs +T (Figure 5D) 
showed a similar distribution pattern to VEGFR2- 
targeted 89Zr-SN38 liposomes alone, with the majority 
of the signal detected in liver. Signal was also evident 
in spleen and lymph nodes suggesting clearance 
predominantly through the MPS system, as 
previously described for liposomes [65-67] and 
VEGFR2-targeted MBs [79]. 
Ex vivo radiocounting was used to quantitate the 
percentage injected dose in different tissues (%ID/g 
tissue) over time. This showed significantly increased 
(approximately twice as much) 89Zr in tumors at all 
time points in the 89Zr-SN38 thMBs +T group 
compared with VEGFR2-targeted 89Zr-SN38 
liposomes alone (Figure 5E). There was also 
significantly increased signal from thMBs in blood at 
one hour post injection compared to free liposomes 
which declined to similar levels by 24 h (Figure 5F) 
suggesting enhanced retention and circulation of 
thMBs in the vascular space compared with targeted 
liposomes alone. By 72 h post-injection, there was a 
significant difference in %ID/g tissue in liver and 
spleen, with relatively less in liver and more in spleen 
in the 89Zr-SN38 thMBs +T group. There was also a 
difference in the ratio of %ID/g in liver and spleen 
compared to tumor (Figure S8B-C) with a significant 
3-fold decrease in liver to tumor ratio %ID at all time 
points. 
Discussion 
We show here how thMBs can enhance the 
efficacy of cytotoxic drugs in vivo by increasing the 
concentration of encapsulated drug in the circulation, 
increasing tumor drug accumulation/retention and 
limiting bioavailability and toxicity in normal tissues. 
Sensitive LC-MS/MS quantification of drugs and 
their metabolites showed that thMBs limited exposure 
in normal tissues by persistent encapsulation of the 
drug, consistent with uptake by the MPS in tissues not 
exposed to US. The extended therapeutic range 
appears to be due to multiple factors that contribute to 
altered drug distribution, metabolism and route of 
elimination, thereby achieving significant therapeutic 
responses with very low doses of cytotoxic drugs. The 
different payloads used in this study demonstrate the 
flexibility and ease of use of a microfluidic production 
platform for generating thMBs in a simple ‘one-pot’ 
approach, with potential for scale-up and a route to 
clinical grade production for human trials. 
These data show that thMB efficacy in vivo can be 
attributed to the combination of several different 
factors. VEGFR2 provided a tumor vasculature target 
for the accumulation, binding and/or anchoring of 
thMBs within the tumor microenvironment. Like 
others [31, 80], we found this interaction to be specific 
compared to control antibodies or non-VEGFR2 
expressing cells and correlated with expression of 
VEGFR2 in tumors. Using VEGFR2 targeting to tumor 
endothelium, thMBs potentially increase the number 
of MBs and liposomes tethered in close proximity to 
the vessel walls. It is this proximity which presumably 
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aids intra- and/or intercellular drug delivery as 
VEGFR2-targeted MB delivery of luciferin showed 
higher initial uptake of luciferin in tumors in the 
absence of an US-trigger. 
 
 
Figure 5. Improved tumor accumulation of 89Zr-labelled SN38 thMBs +T compared with VEGFR2-targeted 89Zr-labelled SN38 liposomes alone. (A) 
Schematic depicting the strategy used for radiolabeling of SN38 liposomes and SN38 thMBs. DSPE was radiolabeled with 89Zr and incorporated into the lipid shell of liposomes 
encapsulating SN38 and used to generate therapeutic MBs. (B) Schematic of the experimental groups used to compare VEGFR2-targeted liposomally encapsulated SN38 
(LE-SN38) with SN38 thMB +T (n = number of mice per group). (C) Schematic of the experimental protocol used (n = 5 animals per time point). The mean (± S.D.) starting 
tumor volume measured by mechanical calipers was 340 mm3 ± 134 mm3. (D) PET image from the thMB +T group at each imaging time point. Signal in the liver, spleen and 
bladder are arrowed, tumor is circled. (E) The percentage injected dose per gram of tissue (%ID/g tissue) in tumor (F) blood (G) liver and (H) spleen were calculated with mean 
and SEM shown. Unpaired T-test tumor, ***p = 0.0006 at 1 h, *p = 0.0432 at 24 h and *p = 0.026 at 72 h. Blood ****p < 0.0001 at 1 h, liver *p = 0.0494 at 72 h, spleen *p = 0.0326 
at 72 h. 
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The US-trigger was shown to be essential for the 
selective effects of VEGFR2 targeted thMB delivery of 
stably encapsulated irinotecan as without the trigger, 
thMBs failed to extend intra-tumoral drug delivery or 
demonstrate enhanced tumor responses. The effects of 
the 5 s US-trigger were long-lasting and widespread 
as shown by the extended drug retention in tumors 
and also in tissues at 72 h. Zhang et al. [25] also 
showed that an US-trigger enhanced tumor responses 
more than endothelial targeting (via RGD) in breast 
cancer xenografts, using liposome-loaded MBs, 
although they were additive in effect. Their study 
used a longer US pulse and a much higher dose of 
paclitaxel than used here to generate a similar 
therapeutic effect [25]. 
US-triggered thMB drug targeting to tumors can 
therefore potentially be achieved on two levels. 
Firstly, molecular interaction occurs with a biological 
receptor on the tumor endothelium (VEGFR2). 
Secondly, physical targeting or site-specific release is 
promoted locally by the external delivery of an 
US-trigger, directed at the bound and flowing 
(unbound) thMBs within the tumor micro-
environment. Together, these increase tumor cell 
uptake and/or retention of drug as seen with 
irinotecan thMBs. In model systems (27), targeting of 
MBs to a surface and exposure to US showed drug 
release and enhanced transport consistent with the in 
vivo effects observed here. 
In addition to VEGFR2 targeting and a localized 
US-trigger, the MB structure itself was shown to play 
an important role in enhancing drug delivery since 
PET radiotracing of thMBs showed a two-fold 
increased concentration in blood compared with 
targeted liposomes alone at 1 hour post US-trigger. 
Our extensive analysis of tumor as well as tissue 
pharmacokinetics, provides insight as to how the 
thMB structure and the US trigger impacts on drug 
distribution, retention and elimination and enhances 
the effects of very low dose thMB delivery compared 
with systemic delivery of free irinotecan or VEGFR2 
targeted SN38 liposomes. 
The mechanism of US-mediated drug delivery is 
being actively studied in vitro using a variety of 
techniques including very high-frame rate 
microscopy. The Brandaris 128 ultra-high-speed- 
camera combined with confocal microscopy has been 
used to study MB oscillations and MB destruction 
under different US parameters as well as free drug 
delivery to cells [81]. Roovers et al. sectioned 
spheroids incubated with drug-loaded MBs and 
exposed to US and found that lipids from the 
liposomes were ‘sonoprinted’ onto the surface of the 
spheroids following which drug release into deeper 
regions was measured [82]. Recently published work 
from our group showed a delay in drug uptake in 
spheroids using drug-loaded MBs compared to free 
drug co-delivered with microbubbles [83] suggesting 
that the attached liposomes were intact following 
US-mediated MB destruction and prior to cellular 
uptake. However, further high-speed two-color 
camera interrogations will be required to elucidate the 
mechanism in real time. 
Several groups have demonstrated the 
importance of the liposomal attachment to MBs [23, 
84, 85] and direct linkage of drug loaded liposomes 
has been shown to improve drug delivery compared 
to co-delivery with free drug [23, 86]. US destruction 
of untargeted DOX-loaded MBs has previously been 
shown to enhance localized drug delivery, although 
the mechanisms were not determined [87]. The local 
energetic stimuli arising from US destruction of 
multiple attached and flowing thMBs in the tumor 
vasculature may involve physical forces (radiation, 
acoustic) jetting or microstreaming [88]. Theoretical 
and single MB experiments in vitro have suggested 
that oscillation of MBs may shed the liposomal 
payload. However, our study uses a short MB 
destruction pulse which is highly unlikely to cause 
MB oscillation alone. The thMB construct itself and 
the fragmentation products arising from US-triggered 
destruction may well underlie the altered PK 
properties of encapsulated drugs delivered in this 
way. It has been shown that in the absence of an 
ultrasound trigger, thMBs delivering a fluorophore 
could be imaged in tumors from 4 h post-injection, 
whereas with a trigger this accumulation occurred 
from the earliest imaging time point (0.5 h), 
irrespective of whether molecular targeting (iRGD) 
was present [89]. 
The efficacy of thMB delivery depends on MB 
design (e.g. size, shell properties, stability) as well as 
the drug itself. We initially chose irinotecan as despite 
its clinical application, the incidence of severe 
diarrhea and neutropenia can limit its use. 
Furthermore, the unpredictable toxicity (despite 
genotyping for high risk glucuronidation deactivating 
enzyme polymorphic variants e.g. UGT1A1 *28/*28) is 
an increasing cause for concern [60]. Although it has 
been successfully encapsulated and liposomal 
formulations have shown reduced toxicity [90], 
localized thMB delivery enables much lower systemic 
doses to be used and reduces the potential for dose- 
limiting toxicities even further. We also encapsulated 
SN38 for direct thMB delivery as it is up to 1000× 
more toxic than irinotecan and demonstrates the 
applicability of this platform for administration of 
difficult to deliver drugs. In addition, the conversion 
to active forms of irinotecan/SN38 (lactone) are 
favored in the more acidic tumor microenvironment 
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and this may also contribute to the reduced toxicity 
seen in healthy tissues at physiological pH (where it is 
very rapidly converted to the carboxylated form [70]) 
as well as the enhanced TGIs seen with such low 
doses. 
In traditional systemic dosing, the effectiveness 
of chemotherapy is determined by the tumor drug 
concentration and high circulating concentrations are 
required to obtain a therapeutic response. Liposomal 
formulations have the benefit of prolonged blood 
circulation time resulting in longer half-life, larger 
AUC, and slower clearance, but suffer from 
unspecified timing and location of drug uptake. 
Preclinical activity of liposomal Irinotecan has been 
shown to be governed by tumor deposition and 
intratumor prodrug conversion. A mechanistic PK 
model showed that concentration and time of 
exposure were major determinants of irinotecan 
efficacy in liposomal formulations and tumor 
permeability and carboxylesterase function limited 
liposomal irinotecan delivery to tumors [64]. As 
shown here, thMBs provide a route to achieving 
efficacy and overcoming these potential barriers to 
drug delivery in the context of irinotecan and SN38. 
With thMB delivery, drug concentrations delivered in 
a single bolus were 2 mg/kg for irinotecan and 0.4 
mg/kg for SN38, far lower than those usually used 
systemically for irinotecan [63, 69] or for liposomal 
irinotecan (3.75 mg/kg) [64] and up to 8 mg/kg with 
liposomal SN38 [75-77]. Although we did observe 
some heterogeneity of response in the treatment 
groups, further much larger studies would be 
required to investigate this. However, statistically 
these results showed that the thMB response does not 
require high circulating levels of drug in plasma to 
achieve therapeutic effects in tumors. 
ThMB delivery may prove particularly effective 
in some clinical settings. For example, the increasingly 
elderly population or those living with cancer would 
benefit from the low drug exposures that allow 
repeated delivery. In addition, there is utility for 
treating recurrent abdominal disease as well as 
metastatic CRC and hepatocellular carcinoma since 
the drug remains encapsulated in normal liver. 
Precisely focused US exposure would be necessary to 
achieve this. 
Molecular imaging of VEGFR2 expression in 
patients has been proposed for antiangiogenic 
therapies [91] and may facilitate stratification of 
patients for thMB treatment. This could be achieved 
with contrast-enhanced ultrasound or multimodal 
imaging. With nearly 60 clinical trials involving MBs 
currently listed as open on the NIH Clinical Trials 
database, including 3 for treatment of gastrointestinal 
cancers, there is ongoing interest in the field of MBs. 
To facilitate translation of thMBs to the clinic, further 
optimization of the approach is warranted for 
example, by investigating alternative US parameters 
such as a higher MI to target central tumor areas [89] 
or fractionated and longer US pulses than were used 
in this study or a focused US beam to limit any 
potential for off-target US triggering. Freeze-drying of 
our drug loaded thMBs has also been achieved (data 
not shown) which will provide a facile way to clinical 
usage as well as aiding production at scale. The use of 
alternative targeting strategies such as affimers [92] or 
lipopeptides [93] should also be explored to reduce 
potential costs of treatment. Further evaluation of 
different liposome payloads for thMBs, thMB 
manufacture and theranostic clinical US systems will 
also aid more rapid translation of this technology for 
clinical use. 
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